Compass Therapeutics Inc.

CMPX | undefined

Price Alert Chart Builder DCF Calculator

At close: undefined

After-hours:

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

undefined%

(1Y)

Rating

Updated: Aug 29, 2026

13.5

Fundamentals Weak

Market Sentiment Neutral

Moat None

Full Analysis

Key Statistics

Market Data

Market Cap $-

1D Range

52W Range

Valuation (TTM)

PE -4.44

PB 1.97

EV/EBITDA -2.17

Valuation (NTM)

Forward PE N/A

Forward PEG -0.42

Price Target $6

Cash Flow

FCF Yield -16.8%

SBC Adj. FCF Yield -20.8%

SBC Impact -23.5%

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y -150.0% | 0.0%

Dil EPS 3Y | 5Y -6.2% | 1.9%

FCF 3Y | 5Y -12.7% | -16.0%

Returns

ROA -38.6%

ROE -38.7%

ROIC -46.1%

Financial Health

Net Cash

$170.25M

Current Ratio 11.22

Interest Coverage 0.00

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating a...

Sector Healthcare

Industry Biotechnology

Employees 39

IPO Date Apr 4, 2021

Website www.compasstherapeutics.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.

Analyst Summary

# of Analysts

Consensus

Buy

Price Target

Upside

0.00%

Buy (6)

Hold (0)

Sell (0)

Analyst Details ➞